Leading Expert in Women s Cancers Appointed Director of Gynecologic Oncology at Perlmutter Cancer Center prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in late stages of one of the most aggressive forms of skin cancer, a new study finds.
Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically (unresectable). The study showed that these patients, all of whom had common genetic changes (BRAFV600 mutations) linked to cancer, were living nearly twice as long without cancer growth as those who continued to have detectable levels.
Gene-based blood test for melanoma spread evaluates treatment progress: Study ANI | Updated: Feb 13, 2021 12:51 IST
Washington [US], February 13 (ANI): A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in the late stages of one of the most aggressive forms of skin cancer, a new study finds.
Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically (unresectable).
Study on gene-based blood test for melanoma spread theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
email article
The antibody-drug conjugate (ADC) enfortumab vedotin significantly improved overall survival (OS) in patients with advanced, previously treated bladder cancer, a large randomized trial showed.
Median OS improved from about 9 months with standard chemotherapy to almost 13 months with enfortumab vedotin-ejfv (Padcev). Median progression-free survival also improved significantly with the ADC, from 3.71 to 5.55 months.
The incidence of treatment-related adverse events (TRAEs) was similar between treatment groups, including grade ≥3 TRAEs, reported Thomas Powles, MD, of Barts Cancer Center and Queen Mary University in London, during the virtual Genitourinary Cancers Symposium (GuCS). The results were published simultaneously in the Enfortumab vedotin is the first drug beyond chemotherapy and immune therapy to show a significant survival advantage in previously treated advanced urothelial cancer, said Powles. This is a big step in the right direction for patie